165 related articles for article (PubMed ID: 6086692)
1. The effects of continuous androgen secretion on the hypothalamic-pituitary axis in woman: evidence from a luteinized thecoma of the ovary.
Dunaif A; Scully RE; Andersen RN; Chapin DS; Crowley WF
J Clin Endocrinol Metab; 1984 Sep; 59(3):389-93. PubMed ID: 6086692
[TBL] [Abstract][Full Text] [Related]
2. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.
Rittmaster RS; Thompson DL
J Clin Endocrinol Metab; 1990 Apr; 70(4):1096-102. PubMed ID: 2156885
[TBL] [Abstract][Full Text] [Related]
3. Ovarian follicular development and the follicular fluid hormones and growth factors in normal women of advanced reproductive age.
Klein NA; Battaglia DE; Miller PB; Branigan EF; Giudice LC; Soules MR
J Clin Endocrinol Metab; 1996 May; 81(5):1946-51. PubMed ID: 8626862
[TBL] [Abstract][Full Text] [Related]
4. Hypothalamic-pituitary-ovarian axis during infancy, early and late prepuberty in an aromatase-deficient girl who is a compound heterocygote for two new point mutations of the CYP19 gene.
Belgorosky A; Pepe C; Marino R; Guercio G; Saraco N; Vaiani E; Rivarola MA
J Clin Endocrinol Metab; 2003 Nov; 88(11):5127-31. PubMed ID: 14602738
[TBL] [Abstract][Full Text] [Related]
5. The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects.
Spinder T; Spijkstra JJ; van den Tweel JG; Burger CW; van Kessel H; Hompes PG; Gooren LJ
J Clin Endocrinol Metab; 1989 Jul; 69(1):151-7. PubMed ID: 2471710
[TBL] [Abstract][Full Text] [Related]
6. A testosterone-secreting, gonadotropin-responsive pure thecoma and polycystic ovarian disease.
Givens JR; Andersen RN; Wiser WL; Donelson AJ; Coleman SA
J Clin Endocrinol Metab; 1975 Nov; 41(5):845-53. PubMed ID: 171277
[TBL] [Abstract][Full Text] [Related]
7. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
8. Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin-releasing hormone receptor antagonist in healthy women with normal ovulation versus women with polycystic ovary syndrome in the early follicular phase.
Sagnella F; Apa R; Guido M; Villa P; Spadoni V; Miceli F; Lanzone A
Fertil Steril; 2009 May; 91(5):1857-63. PubMed ID: 18538325
[TBL] [Abstract][Full Text] [Related]
9. Androgen response in polycystic ovarian syndrome to FSH treatment after LHRH agonist suppression.
Hamori M; Zwirner M; Clédon P; Tinneberg HR
Int J Fertil; 1992; 37(3):171-5. PubMed ID: 1355764
[TBL] [Abstract][Full Text] [Related]
10. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
[TBL] [Abstract][Full Text] [Related]
11. Virilizing luteinized thecoma of the ovary in a 15-year-old female: a case report.
McGee J; Fleming NA; Senterman M; Black AY
J Pediatr Adolesc Gynecol; 2009 Oct; 22(5):e107-10. PubMed ID: 19576809
[TBL] [Abstract][Full Text] [Related]
12. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome.
Adams JM; Taylor AE; Crowley WF; Hall JE
J Clin Endocrinol Metab; 2004 Sep; 89(9):4343-50. PubMed ID: 15356031
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
[TBL] [Abstract][Full Text] [Related]
14. Increased anti-Mullerian hormone levels and ovarian size in a subgroup of women with functional hypothalamic amenorrhea: further identification of the link between polycystic ovary syndrome and functional hypothalamic amenorrhea.
Carmina E; Fruzzetti F; Lobo RA
Am J Obstet Gynecol; 2016 Jun; 214(6):714.e1-6. PubMed ID: 26767792
[TBL] [Abstract][Full Text] [Related]
15. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome.
Veldhuis JD; Pincus SM; Garcia-Rudaz MC; Ropelato MG; Escobar ME; Barontini M
J Clin Endocrinol Metab; 2001 Aug; 86(8):3772-8. PubMed ID: 11502810
[TBL] [Abstract][Full Text] [Related]
16. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty.
Blank SK; McCartney CR; Helm KD; Marshall JC
Semin Reprod Med; 2007 Sep; 25(5):352-9. PubMed ID: 17710731
[TBL] [Abstract][Full Text] [Related]
18. The effects of ovarian wedge resection on circulating gonadotropin and ovarian steroid levels in patients with polycystic ovary syndrome.
Judd HL; Rigg LA; Anderson DC; Yen SS
J Clin Endocrinol Metab; 1976 Aug; 43(2):347-55. PubMed ID: 950366
[TBL] [Abstract][Full Text] [Related]
19. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours.
Pascale MM; Pugeat M; Roberts M; Rousset H; Déchaud H; Dutrieux-Berger N; Tourniaire J
Clin Endocrinol (Oxf); 1994 Nov; 41(5):571-6. PubMed ID: 7828344
[TBL] [Abstract][Full Text] [Related]
20. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
